DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for type 2 diabetes mellitus — screening already-approved drugs against its 37-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleType 2 diabetes mellitus maps to a 37-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedMetforminApproved drugapprovedGlipizideSulfonylurea receptor 1, Kir6.2 blockerapprovedSunitinibApproved drug
Structures already discussed alongside type 2 diabetes mellitus in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
KIT kinase domain — Sunitinib has a real, experimentally solved structure in complex with this target (PDB 3G0E, 1.6 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet b49drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3G0E · 1.6 Å · ligand Sunitinib (B49). Experimental structure, not a prediction.
What the evidence adds up to
A 2018 review of type 2 diabetes management strategies reports that antidiabetic drugs account for the second largest market by sales in the pharmaceutical industry after cancer. The review identifies several novel therapeutic targets for producing newer generation antidiabetic agents but does not present any original patient data, survival figures, or response rates. No specific drug is tested or shown to be effective in this paper.
A 2008 review of oral agents in late-stage development for type 2 diabetes examines dipeptidyl peptidase-IV inhibitors, CB1 cannabinoid receptor blockers, and bile acid sequestrants. The review notes that despite existing treatment, control of hyperglycemia and associated conditions remains suboptimal in the majority of patients. The paper discusses emerging therapies targeting insulin resistance, glycogenolysis, and gluconeogenesis but provides no concrete numbers on efficacy, sample sizes, or outcomes from any trial.
A 2004 paper identifies insulin receptor substrate 2 (IRS2) as a central player in the pathophysiology of type 2 diabetes, linking obesity, insulin and leptin resistance, and β cell degeneration. This is a molecular biology review, not a clinical trial; it reports no patient data, no survival or response rates, and no drug intervention.
What is still missing: large-scale, randomised controlled trials that test specific repurposed drugs in defined patient populations, with clear stratification by disease stage, obesity status, and insulin resistance. Funding for such trials, rather than further reviews of molecular targets or market analyses, is needed to determine whether any existing drug can improve outcomes in type 2 diabetes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Drug Targets · 2018 · 40 citations
Current Strategies and Drug Targets in the Management of Type 2 Diabetes Mellitus
AbstractBACKGROUND: Diabetes is one of the major concerns worldwide which leads to increased level of blood glucose due to deficiency of insulin and the development of insulin resistance in diabetic individuals. Basically, its impact arises due to rapid urbanization, improper diet intake, and increasingly inactive lifestyle. Diabetic patients develop serious complications with the development of disease at later stages, such as obesity, the risk of stroke and heart failure. Globally, an estimated 422 million adults are living with type 2 diabetes mellitus. METHODS: We searched the scientific database using relevant keywords. Among the searched literature, only peer-reviewed papers were collected which addresses our questions. The retrieved quality papers were screened and analyzed critically. The key findings of these studies are included along with the importance. RESULTS: The quality research paper included in the review, particularly the antidiabetic drugs which account for the second largest market by sales in the pharmaceutical industry after cancer. So the research came up with several novel therapeutic targets for the management of type 2 diabetes, to produce newer generation antidiabetic drug by offering a new concept for developing new drug candidates. CONCLUSION: This review discusses the strategies and future perspectives in the management of type 2 diabetes mellitus particularly antidiabetic agents which are helpful for the betterment of diabetic patients.
Japanese Journal of Clinical Oncology · 2012 · 31 citations
Impact of Sunitinib Treatment on Blood Glucose Levels in Patients with Metastatic Renal Cell Carcinoma
AbstractOBJECTIVE: To investigate the effects of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma. METHODS: We reviewed the records of 48 patients who received sunitinib treatment for metastatic renal cell carcinoma between April 2007 and December 2010 at our institution. Patients' data including diabetic status, diabetes mellitus medication and mean blood glucose levels before, during and after the treatment with sunitinib were assessed. RESULTS: In 10 of the 48 (20.8%) patients who were diabetic, the blood glucose level was observed to be significantly decreased after 4 weeks of sunitinib treatment with the mean decrease in blood glucose level being 76.1 ± 29.0 mg/dl (P = 0.002). Subsequently, after a 2-week off-treatment period, the mean blood glucose level rebound and increased (21.9 ± 6.3 mg/dl, P = 0.038) in these 10 patients. With sunitinib treatment, one patient was able to discontinue diabetes mellitus medication completely during a 4-week treatment period, and three other patients had dosages of their oral diabetes mellitus medication reduced. Among 38 non-diabetic patients, no significant changes in blood glucose levels were observed during both the 4-week sunitinib treatment period and the 2-week off-treatment period. No severe hypoglycemic episode was observed among our subjects. CONCLUSIONS: Sunitinib treatment in diabetic patients with metastatic renal cell carcinoma may result in significantly decreased blood glucose levels. Thus, blood glucose levels should be checked more vigilantly in diabetic patients undergoing sunitinib treatment to adjust diabetes mellitus medications as needed. Further investigation via a larger scaled, prospective study would be needed.
Current Medical Research and Opinion · 2008 · 10 citations
Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease
AbstractBACKGROUND: Type 2 diabetes is often accompanied by co-morbid conditions such as hypertension and dyslipidemia, which, coupled with persistent hyperglycemia, result in significant macrovascular and microvascular complications. Type 2 diabetes treatments focus primarily on controlling hyperglycemia, hypertension, and dyslipidemia to stabilize the disease and minimize complications. Despite treatment, control of hyperglycemia and the conditions associated with type 2 diabetes are suboptimal in the majority of patients. Research efforts have concentrated on the development of new therapies for type 2 diabetes, including agents that could be used both as monotherapy and in combination with established oral antidiabetic agents to improve glycemic control and reduce the disease burden on patients. OBJECTIVE: To review published literature on oral agents in development for type 2 diabetes, with a focus on their mechanism of action and impact on concomitant risk factors. METHODS: After identifying oral agents in late-stage development for type 2 diabetes using the R&D Insight database, a literature review was conducted through PubMed for studies (preferably randomized, controlled trials) on dipeptidyl peptidase-IV inhibitors, CB(1) cannabinoid receptor blockers, and bile acid sequestrants. Where limited published data were available, abstracts from recent major conferences were searched. Other emerging therapies targeting pathways involved in modifying insulin resistance, glycogenolysis, and gluconeogenesis are also discussed. CONCLUSIONS: A variety of novel therapies for type 2 diabetes are in development, which will provide patients and diabetes care providers more choices for the management of this disease. Importantly, many of these treatments offer the potential to significantly improve multiple metabolic parameters.
Journal of Clinical Investigation · 2004 · 8 citations · open access
IRS2 takes center stage in the development of type 2 diabetes
AbstractThe etiology of type 2 diabetes is characterized by obesity, insulin and leptin resistance, and compensatory β cell hyperplasia followed by islet degeneration, resulting in the eventual dysregulation of glucose and lipid homeostasis. The recent identification of insulin receptor substrate 2 (IRS2) as a central player in the pathophysiology of many of these processes suggests a potentially unifying molecular link underlying the initiation and progression of type 2 diabetes.
American Journal of Health-System Pharmacy · 2012 · 4 citations
Combination exenatide–sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus
AbstractPURPOSE: The case of a patient with type 2 diabetes mellitus who received combination exenatide-sitagliptin with glipizide is reported. SUMMARY: A 55-year-old, 204-lb Caucasian woman arrived at a clinic with polydipsia. Her blood glucose concentration was 450 mg/dL and her glycosylated hemoglobin (HbA(1c)) value was 13.4%. She was diagnosed with type 2 diabetes mellitus and started on metformin hydrochloride 500 mg orally twice daily. Metformin was later discontinued due to elevated liver function test values. Sitagliptin 100 mg daily was substituted, and glipizide was later added and its dosage adjusted over the next several months. After six months, her HbA(1c) value had decreased to 9.3% and she had gained 14 lb. Exenatide was then added to her regimen, and the dosage was adjusted to 10 μg subcutaneously twice daily. Two months after the initiation of sitagliptin, glipizide, and exenatide, the patient had lost 10 lb, reported significant improvements in self-monitored blood glucose readings, and required a reduction in glipizide dosage despite no reported therapeutic lifestyle changes. Seven months after the initiation of exenatide, sitagliptin, and glipizide, her HbA(1c) value was 7.4%. Triple therapy resulted in a total HbA(1c) value reduction of 1.9%, a weight loss of 11 lb, and normalized liver function test values. The patient's high blood pressure was treated with losartan and remained at goal throughout the duration of this report. CONCLUSION: In a patient with type 2 diabetes mellitus, the addition of the incretin mimetic exenatide and the dipeptidyl peptidase-4 inhibitor sitagliptin to glipizide therapy appeared effective and safe.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
